Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia
Rhea-AI Summary
Evaxion (NASDAQ: EVAX) reported new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine candidate for acute myeloid leukemia. Developed using its AI-Immunology platform, EVX-04 targets multiple endogenous retrovirus tumor antigens and shows correct expression, secretion, immune activation, and targeted cell-killing in preclinical models.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- EVX-04 shows complete expression, transcription and translation in human cells
- Vaccine antigens are secreted, enabling immune recognition and activation
- ERV antigens induce specific immune responses in mice and human cells
- Vaccine-induced immune cells mediate targeted tumor cell-killing in preclinical tests
- Regulatory filing preparations for EVX-04 clinical testing are underway
Negative
- EVX-04 remains at the preclinical stage with no human clinical data yet
News Market Reaction – EVAX
On the day this news was published, EVAX declined 4.75%, reflecting a moderate negative market reaction. Argus tracked a peak move of +8.3% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $32.53M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | EVX-04 data preview | Positive | -1.3% | Announcement of upcoming EVX-04 preclinical data at EHA 2026. |
| May 07 | Q1 2026 earnings | Neutral | -7.7% | Quarterly results and business update focused on AI-Immunology™ platform. |
| May 04 | Earnings date set | Neutral | +1.7% | Scheduling of Q1 2026 results release and investor call. |
| Apr 27 | Management change | Neutral | +3.7% | Promotion of Birgitte Rønø to combined CSO and COO role. |
| Apr 17 | EVX-01 phase 2 data | Positive | +7.5% | Strong EVX-01 immune-response and response-rate data in melanoma. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive R&D news has previously coincided with gains, while earnings and event updates have been mixed in their impact.
Over the last few months, Evaxion reported several AI-Immunology™-driven milestones and corporate updates. On Apr 17, phase 2 EVX-01 data with strong immune responses and a 75% ORR saw shares rise. A management promotion on Apr 27 and an earnings date announcement on May 4 also aligned with modest gains. However, the May 7 Q1 2026 earnings and a May 12 preview of EVX-04 data were followed by declines, showing that not all positive narrative updates translated into immediate price strength.
Regulatory & Risk Context
Key Terms
acute myeloid leukemia medical
endogenous retrovirus medical
in vivo medical
in vitro medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- EVX-04 is successfully expressed and secreted in human cells enabling immune recognition and activation
- The vaccine antigens drive specific immune responses across different human immune profiles and induce targeted cell-killing
- Poster presentation at the European Hematology Association (EHA) 2026 Congress, taking place in Stockholm, Sweden
COPENHAGEN, Denmark, June 11, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML). Developed with AI-Immunology™, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigens from the dark genome.
The new data demonstrates EVX-04’s complete expression in human cells, including correct transcription and translation. Further, EVX-04 is secreted in human cells, enabling immune recognition and activation.
The data also shows that all ERV antigens included in EVX-04 drive specific immune responses both in mice (in vivo) and human cells (in vitro) across different human immune profiles. These vaccine-induced immune cells mediate targeted cell-killing, highlighting EVX-04’s potential as a new effective therapeutic cancer vaccine.
Data will be presented at a poster presentation at the European Hematology Association (EHA) 2026 Congress taking place in Stockholm, Sweden, on June 13, 2026.
“We are excited to share the new data on EVX-04, which could potentially greatly improve treatment options for AML patients. We are successfully executing the preclinical activities and in parallel preparing the regulatory filing for clinical testing and are looking forward to discussing the data and the program at the EHA congress,” says Birgitte Rønø, CSO & COO of Evaxion.
About EVX-04
Developed with our AI-Immunology™ platform, EVX-04 targets non-conventional endogenous retrovirus (ERV) tumor antigens from the dark genome. These antigens are selectively expressed in specific tumors but absent in normal tissue, making them highly attractive therapeutic cancer targets.
Using sequencing data from AML patients, our AI-Immunology™ platform first identified ERV tumor antigens and then mined these to determine smaller fragments with the potential for immune recognition. From the five million ERV antigen fragments discovered, AI-Immunology™ combined and selected 16 optimal sets of ERV fragments based on their cross-patient relevance and immunogenic potential. All 16 ERV fragments included in EVX-04 elicit a specific immune response and EVX-04 prevents tumor growth in preclinical tumor models.
The data-driven target selection ensures that EVX-04 provides broad tumor coverage regardless of immune and tumor ERV antigen differences across patients. Thus, EVX-04 is developed as an off-the-shelf vaccine pre-produced and ready for immediate administration after diagnosis. The same concept is broadly applicable across cancers where immunotherapies remain inadequate and conserved immunogenic antigens can be identified.
About AML
AML is an aggressive hematologic malignancy characterized by clonal expansion of undifferentiated myeloid precursor cells (AML blasts) in the bone marrow. It has poor outcomes for patients ineligible for intensive chemotherapy or stem cell transplantation, highlighting the need for novel and less toxic treatment strategies.
AML is the most frequent leukemia, occurring across all age groups, however, predominantly observed in older adults (median age at diagnosis of 68 years).
Approximately
Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
About Evaxion
Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.
With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development.
We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.
For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
